Hippocampal serotonin depletion is related to the presence of generalized tonic-clonic seizures, but not to psychiatric disorders in patients with temporal lobe epilepsy

Epilepsy Research

Volumn 111, Issue , 2015, Pages 18-25

  da Fonseca, Natascha C ^a   Joaquim, Helena P G ^a   Talib, Leda L ^a   de Vincentiis, Silvia ^a   Gattaz, Wagner F ^a   Valente, Kette D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; HALOPERIDOL; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; RISPERIDONE; SEROTONIN; SERTRALINE; TOPIRAMATE; VALPROIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPAL SCLEROSIS; HIPPOCAMPUS; HUMAN; MALE; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOSIS; SAMPLE SIZE; SEROTONIN BRAIN LEVEL; STUDENT T TEST; TEMPORAL LOBE EPILEPSY; TONIC CLONIC SEIZURE; ADOLESCENT; AGED; CHILD; COMPLICATION; DEFICIENCY; EPILEPSY, TEMPORAL LOBE; METABOLISM; MIDDLE AGED; SEIZURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPRESSION; EPILEPSY, TEMPORAL LOBE; FEMALE; HIPPOCAMPUS; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; SEIZURES; SEROTONIN; YOUNG ADULT;

EID: 84924311057     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2014.12.013     Document Type: Article

References (40)

1. Bagdy G., Kecskemeti V., Riba P., Jakus R. Serotonin and epilepsy. J. Neurochem. 2007, 100(4):857-873.
2. Beleza P. Refractory epilepsy: a clinically oriented review. Eur. Neurol. 2009, 62(2):65-71.
3. Broderick P.A., Pacia S.V., Doyle W.K., Devinsky O. Monoamine neurotransmitters in resected hippocampal subparcellations from neocortical and mesial temporal lobe epilepsy patients: in situ microvoltammetric studies. Brain Res. 2000, 878(1-2):48-63.
4. Browning R.A., Wood A.V., Merrill M.A., Dailey J.W., Jobe P.C. Enhancement of the anticonvulsant effect of fluoxetine following blockade of 5HT1a receptors. Eur. J. Pharmacol. 1997, 336(1):1-6.
5. Cloix J.F., Tahi Z., Boissonnet A., Hévor T. Brain glycogen and neurotransmitter levels in fast and slo methionine sulfoximine-selected mice. Exp. Neurol. 2010, 225(2):274-283.
6. Clough R.W., Peterson B.R., Steenbergen J.L., Jobe P.C., Browning R.A., Mishra P.K. Neurite extension of developing noradrenergic neurons is impaired in genetically epilepsy-prone rats (GEPR-3s): an in vitro study in locus coeruleus. Epilepsy Res. 1998, 29(2):135-146.
7. Coffey L.L., Reith M.E., Chen N.H., Mishra P.K., Jobe P.C. Amygdala kindling of forebrain seizures and the occurrence of brainstem seizures in genetically epilepsy-prone rats. Epilepsia 1996, 37(2):189-197.
8. Dailey J.W., Reigel C.E., Mishra P.K., et al. Neurology of seizure predisposition in the genetically epilepsy-pone rat. Epilepsy Res. 1989, 3:3-17.
9. Dailey J.W., Mishra P.K., Ko K.H., Penny J.E., Jobe P.C. Serotoninergic abnormalities in the central nervous system of seizure-naive genetically epilepsy prone rats. Life Sci. 1992, 50(4):319-326.
10. Drevets W.C., Frank E., Price J., Kupfer D.J., Holt D., Greer P.J., Huang Y., Gaultier C., Mathis C. PET imaging of serotonin 1A receptor binding in depression. Biol. Psychiatry 1999, 46(10):1375-1387.
11. Favale E., Rubino V., Mainardi P., Lunardi G., Albano C. Anticonvulsivant effect of fluoxetine in humans. Neurology 1995, 45(10):1926-1927.
12. Favale E., Audenino D., Cocito L., Albano C. The anticonvulsant effect of citalopram as an indirect evidence of serotoninergic impairment in human epileptogenesis. Seizure 2003, 12(5):316-318.
13. 2 activity in the hippocampus of patients with temporal lobe epilepsy and psychosis. J. Psychiatr. Res. 2011, 45(12):1617-1620.
14. Hasler G., Bonwetsch R., Giovacchini G., Toczek M.T., Bagic A., Lucknbaugh D.A., Drevets W.C., Theodore W.H. 5HT1A Receptor binding in temporal lobe epilepsy patients with and without major depression. Biol. Psychiatry 2007, 62(11):1258-1264.
15. Hung C.F., Lung F.W., Chen C.H., O'Nions E., Hung T.H., Chong M.Y., Wu C.K., When J.K., Lin P.Y. Association between suicide attempt and a tri-allelic functional polymorphism in serotonin transporter gene promoter in Chinese patients with schizophrenia. Neurosci. Lett. 2011, 504(3):242-246.
16. Jobe P.C., Dailey J.W. Genetically epilepsy-prone rats (GEPRs) in drug research. CNS Drug Rev 2000, 6(3):241-260.
17. Jobe P.C., Dailey J.W., Reigel C.E. Noradrenergic and serotoninergic determinants of seizure susceptibility and severity in genetically epilepsy-prone rats. Life Sci. 1986, 39(9):775-782.
18. Jobe P.C., Mishra P.K., Adams-Curtis L.E., Deoskar V.U., Ko K.H., Browning R.A., Dailey J.W. The genetically epilepsy-prone rat (GEPR). Ital. J. Neurol. Sci. 1995, 16(1-2):91-99.
19. Kandratavicius L., Rosa-Neto P., Monteiro M.R., Guiot M.C., Assirti J.A., Calotti C.G., Kobayashi E., Leite J.P. Distinct increased metabotropic glutamate receptor type 5 (mGluR5) in temporal lobe epilepsy with and without hippocampal sclerosis. Hippocampus 2013, 23(12):1212-1230.
20. Kandratavicius L., Monteiro M.R., Assirati J.A., Carlotti C.G., Hallak J.E., Leite J.P. Neurotrophins in mesial temporal lobe epilepsy with and without psychiatric comorbidities. J. Neuropathol. Exp Neurol. 2013, 72(11):1029-1042.
21. Kwan P., Arzimanoglou A., Berg A.T., Brodie M.J., Allen Hauser W., Mathern G., Moshé S.L., Perucca E., Wiebe S., French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE Commission on Therapeutics Strategies. Epilepsia 2010, 51(6):1069-1077.
22. Li B., Wang L., Sun Z., Zhou Y., Shao D., Zhao J., Song Y., Lv J., Dong X., Liu C., Wang P., Zhang X., Cui R. The anticonvulsant effects of SR 57227 on pentylenetetrazole-induced seizure in mice. PLoS ONE 2014, 9(4):e93158.
23. Louw D., Sutherland G.R., Glavin G.B., Girvin J. A study of monoamines metabolism in human epilepsy. Can. J. Neurol. Sci. 1989, 16(4):394-397.
24. Merrill M.A., Clough R.W., Dailey J.W., Jobe P.C., Browning R.A. Localization of the serotoninergic terminal fields modulating seizures in the genetically epilepsy-prone rat. Epilepsy Res. 2007, 76(2-3):93-102.
25. Mori A., Hiramatsu M., Namba S., Nishimoto A., Ohmoto T., Mayanagi Y., Asakura T. Decreased dopamine level in the epileptic focus. Res. Commun. Chem. Pathol. Pharmacol. 1987, 56(2):157-164.
26. Naffah-Mazzacoratti M.G., Amado D., Culdert A., Gronich G., Marino R., Calderazzo L., Cavalheiro E.A. Monoamines and their metabolites in cerebrospinal fluid and temporal cortex of epileptic patients. Epilepsy Res. 1996, 25(2):133-137.
27. Pacia S.V., Dovle W.K., Broderick P.A. Biogenic amines in the human neocortex in paients with neocortical and mesial temporal lobe epilepsy: identification with in situ microvoltammetry. Brain Res. 2001, 899(1-2):106-111.
28. Palomero-Gallagher N., Schleicher A., Bidmon H.J., Pannek H.W., Hans V., Gorji A., Speckmann E.J., Zilles K. Multireceptor analysis in human neocortex reveals complex alterations of receptor ligand binding in focal epilepsies. Epilepsia 2012, 3(11):1987-1997.
29. Picard M., Cloix J.F., Hevor T.K. Serotonergic neurotransmission plays a major role in the action of the glycogenic convulsant methionine sulfoximine. Neurosci. Res. 2011, 70(3):313-320.
30. Pintor M., Mefford I.N., Hutter I., Pocotte S.L., Wyler A.R., Nadi N.S. Levels of biogenic amines, their metabolites, and tyrosine hydroxylase in the human epileptic temporal cortex. Synapse 1990, 5(2):152-156.
31. Rocha L., Alonso-Venegas M., Villeda-Hernández J., Mújica M., Cisneros-Franco J.M., López-Gomez M., Zavala-Tecuapetla C., Frías-Soria C.L., Segovia-Vila J., Borsodi A. Dopamine abnormalities in the neocortex of patients with temporal lobe epilepsy. Neurobiol. Dis. 2012, 45(1):499-507.
32. Ryu J.R., Jobe P.C., Milbrandt J.C., Mishra P.K., Clough R.W., Browning R.A., Dailey J.W., Seo D.O., Ko K.H. Morphological deficits in noradrenergic neurons in GEPR-9s stem from abnormalities in both the locus coeruleus and its target tissues. Exp. Neurol. 1999, 156(1):84-91.
33. Sargent P.A., Kjaer K.H., Bench C.J., Rabiner E.A., Messa C., Meyer J., Gunn R.N., Grasby P.M., Cowen P.J. Brain serotonin 1A receptor binding measured by positron emission tomography with [11C]WAY-100635. Arch. Gen. Psychiatry 2000, 57(2):174-180.
34. Schenkel L.C., Bragatti J.A., Becker J.A., Torres C.M., Martin K.C., Souza A.C., Manfro G.G., Leistner-Segal S., Bianchin M.M. Serotonin gene polymorphisms and psychiatry comomorbidities in temporal lobe epilepsy. Epilepsy Res. 2011, 12(5):1-7.
35. Smolders I., Clinckers R., Meurs A., De Bundel D., Portelli J., Ebinger G., Michotte Y. Direct enhancement of hippocampal dopamine or serotonin levels as a pharmacodynamic measure of combined antidepressant-anticonvulsant action. Neuropharmacology 2008, 54(6):1017-1028.
36. Specchio L.M., Iudice A., Specchio N., La Neve A., Spinelli A., Galli R., Rocchi R., Ulivelli M., de Tommaso M., Pizzanelli C., Murri L. Citalopram as treatment of depression in patients with epilepsy. Clin. Neuropharmacol. 2004, 27(3):133-136.
37. Trindade-Filho E.M., Castro-Neto E.F., Carvalho R., Lima E., Scorza F.A., Amado D., Naffah-Mazzacorattti M.G., Cavalheiro E.A. Serotonin depletion effects on the pilocarpine model of epilepsy. Epilepsy Res. 2008, 82(2-3):194-199.
38. Veriano A., Capovilla G., Fattore C., Franco V., Gambardella A., Guerrini R., La Briola F., Ladogana M., Rosati E., Specchio L.M., Striano S., Perucca E. Characteristics of a large population of patients with refractory epilepsy attending tertiary referral centers in Italy. Epilepsia 2010, 51(5):921-925.
39. Vermoesen K., Messie A., Smolders I., Clinckers R. The antidepressants citalopram and reboxetine reduce seizure frequency in rats with chronic epilepsy. Epilepsia 2012, 53(5):870-878.
40. Yan Q.S., Jobe P.C., Dailey J.W. Evidence that a serotonergic mechanism is involved in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats. Eur. J. Pharmacol. 1994, 252(1):105-112.